Randomized Trials of Approved Technology for the Purpose of Class I Guidelines | The PROTECT IV Case Study

Disclosure(s):

Gregg W. Stone, MD, FACC, MSCAI: Abbott, Abiomed, Cardiovascular Systems Inc, Phillips, Vascular Dynamics, Pulnovo, V-wave: Research support to Mount Sinai Hospital (Ongoing); Apollo Therapeutics, Cardiac Success, Occlutech, Millennia Biopharma, RCE, Ablative Solutions, Abbott: Consultant (Terminated); Boehringer Ingelheim: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Cardiac Success, Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Valfix, Xenter: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Shockwave, Biosense-Webster, Bioventrix: Research support to Mount Sinai Hospital (Terminated); Valfix, Zoll, HeartFlow, Shockwave, Ancora, Impulse Dynamics, Adona Medical, Oxitope, HighLife, Elixir, Elucid Bio, Aria, Alleviant, FBR Medical: Consultant (Ongoing)